• About
    • Mission
    • Leadership
    • Careers
    • Clinical Advisory Board
    • News
    • Media & Press
    • Events
  • Viveve Solutions
    • Viveve System
    • InControl
  • Healthcare Providers
    • Clinical Studies
    • Become a Provider
    • Manage Your Listing
    • Hub Login
    • FAQs
    • Product Feedback
  • Patients
    • Blog
    • Find A Provider
    • Refer A Provider
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact Us
    • FAQs
    • Viveve Hub
    • Submit a Product Experience
  • Product Indication
Select Page
Viveve | US

Publications

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Clinical Advisory Board
    • Medical Consultants
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts
The Top 25 Women Leaders in Medical Devices of 2022

The Top 25 Women Leaders in Medical Devices of 2022

Viveve’s Senior Vice President of Regulatory and Quality Affairs, Suzon Lommel, recognized for second consecutive year for leadership and contributions in medical device industry.

The Healthcare Technology Report, January 11, 2022 (https://thehealthcaretechnologyreport.com/the-top-25-women-leaders-in-medical-devices-of-2022/)

The Top 50 Healthcare Technology CEOs of 2021

The Top 50 Healthcare Technology CEOs of 2021

Scott Durbin, Viveve’s CEO listed in elite group of highly accomplished innovative leaders in healthcare technology industry.

The Healthcare Technology Report, April 14, 2021 (https://thehealthcaretechnologyreport.com/the-top-50-healthcare-technology-ceos-of-2021/)

The Top 25 Women Leaders in Medical Devices of 2021

The Top 25 Women Leaders in Medical Devices of 2021

Viveve’s Senior Vice President of Regulatory and Quality Affairs, Suzon Lommel, recognized for professional expertise and outstanding contributions in medical device industry. 

The Healthcare Technology Report, January 26, 2021 (https://thehealthcaretechnologyreport.com/the-top-25-women-leaders-in-medical-devices-of-2021/)

A 12-month Feasibility Study to Investigate the Effectiveness of Cryogen-cooled Monopolar Radiofrequency Treatment for Female Stress Urinary Incontinence

A 12-month Feasibility Study to Investigate the Effectiveness of Cryogen-cooled Monopolar Radiofrequency Treatment for Female Stress Urinary Incontinence

Bruce B. Allan, PhD, MD, FRCS(C), Stacie Bell, PhD, Kathryn Husarek, PhD

Original Research Publication: Canadian Urological Association Journal, July, 2020 (Can Urol Assoc J 2020;14(7):E313-8.) Published online February 4, 2020.

Early Feasibility Study to Evaluate the Viveve System for Female Stress Urinary Incontinence:  Interim 6-Month Report

Early Feasibility Study to Evaluate the Viveve System for Female Stress Urinary Incontinence: Interim 6-Month Report

Bruce B. Allan, PhD, MD, FRCS(C), Stacie Bell, PhD, Kathryn Husarek, PhD

Publication: Journal of Women’s Health 2020; Vol 29, No 3:383-389

Viveve and Its New CEO are Pioneering Women’s Intimate Health

Viveve and Its New CEO are Pioneering Women’s Intimate Health

Published interview with Scott Durbin, Viveve’s CEO and Director
CEOCFO Magazine, September 16, 2019 (ceocfointerviews.com)

Feasibility Study of Non-Ablative Cryogen-Cooled Monopolar Radiofrequency Treatment for Stress Urinary Incontinence (SUI): Interim 12-Month Results

Feasibility Study of Non-Ablative Cryogen-Cooled Monopolar Radiofrequency Treatment for Stress Urinary Incontinence (SUI): Interim 12-Month Results

Bruce B. Allan, PhD, MD, FRCS(C), Stacie Bell, PhD, Kathryn Husarek, PhD

Poster Presentation: Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) February 26 – March 2, 2019 Miami, FL

Safety and Mechanism of Action of Energy-Based Devices for the Treatment of Urogynecologic Conditions

Safety and Mechanism of Action of Energy-Based Devices for the Treatment of Urogynecologic Conditions

Maria Canter, MD, FPMRS, FACOG, MSc, Steven Lathers, PhD, Stacie Bell, PhD

Poster Presentation: Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) February 26 – March 2, 2019 Miami, FL

Feasibility Study of Non-Ablative Cryogen-Cooled Monopolar Radiofrequency Treatment for Stress Urinary Incontinence (SUI)

Feasibility Study of Non-Ablative Cryogen-Cooled Monopolar Radiofrequency Treatment for Stress Urinary Incontinence (SUI)

Bruce B. Allan, PhD, MD, FRCS(C), Stacie Bell, PhD

Poster Presentation: The 43rd Annual Meeting of International Urogynecological Association (IUGA)  June 27-30, 2018 Vienna, Austria

Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial  (SFSI domains subanalysis)

Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial (SFSI domains subanalysis)

Michael L. Krychman, MD, Christopher G. Rowan, PhD, Bruce B. Allan, MD, PhD, FRCS(C), Scott Durbin, MPH, Ashley Yacoubian, BSc, and Deborah Wilkerson, PhD

Publication: Journal of Women’s Health 2018; 27:297-304

RSS
  • 1
  • 2
  • Next »

Viveve

A Global Women’s Intimate Health Company

Terms of Use | Privacy Policy
© 2022 Viveve Solutions. All Rights Reserved.

  • About
  • Viveve Solutions
  • Providers
  • Patients
  • Investors
  • Careers
  • Contact Us



  • Hub Login
  • Product Feedback

345 Inverness Drive South
Building B, Suite 250
Englewood, CO 80112

The Viveve System is indicated for general surgery for electrocoagulation and hemostasis in the United States.

The Viveve® System is an internationally patented cryogen-cooled monopolar radiofrequency (CMRF) energy-based platform device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan and China. In the United States the Viveve System is cleared by the FDA for general surgery procedures for electrocoagulation and hemostasis. International approvals and clearances include vaginal laxity and/or improvement of sexual function indications. In Argentina improvement of urinary incontinence in women is also an approved indication.

Translate »